This feature highlights changes in clinical trial organizations’ personnel.
Michael Amoroso has been named chief commercial officer of Abeona Therapeutics. Prior to this role, Amoroso was senior vice president and head of worldwide commercial cell therapy at Gilead Sciences’ Kite.
Tracey Mullen, former chief operating officer of Abveris, has been promoted to CEO of the company. Garren Hilow has moved from his role of CEO at the company to the role of chief business officer.
Narinder Singh, who previously served as senior vice president of pharmaceutical sciences and manufacturing at Genocea Biosciences, has been hired by Aimmune to assume the role of executive vice president of technical operations.
Akcea Therapeutics has named William Andrews as its new chief medical officer. Andrews was most recently chief medical officer at Acer Therapeutics.
Dennis Mulroy has been appointed chief financial officer of AnaptysBio. Prior to joining AnaptysBio, Mulroy was chief financial officer of La Jolla Pharmaceutical. AnaptysBio also named Eric Loumeau chief operating officer of the company. Loumeau was most recently general counsel and chief compliance officer of Otonomy.
Antengene has named Dirk Hoenemann head of medical affairs for the Asia Pacific region and early clinical development. Hoenemann most recently served as the lead of development of the early clinical development programs for the Asia Pacific region at Celgene.
Erik Spek has been tapped by Arrakis Therapeutics to serve as the company’s vice president of legal and intellectual property. Spek was senior vice president and head of legal affairs and intellectual property at Vedanta Biosciences prior to joining Arrakis.
Chris Morabito has been appointed chief medical officer of Cardurion Pharmaceuticals. Most recently, Morabito was senior vice president and head of research and development and plasma-derived therapies of Takeda Pharmaceuticals.
Myron Czuczman has been named chief medical officer and executive vice president of Citius Pharmaceuticals. Czuczman previously served as therapeutic area head and vice president of clinical research and development of the global lymphoma/CLL program at Celgene.
COVAXX has named Farshad Guirakhoo as its new chief scientific officer. Guirakhoo was recently the chief scientific officer of GeoVax.
Cytovance Biologics has named John Mott vice president of development. Prior to joining Cytovance, Mott was vice president of laboratory services at Aragen Bioscience. Yuk Chun Chiu has also been enlisted as Cytovance’s vice president of manufacturing operations. Chiu recently served as the director of manufacturing and engineering at AstraZeneca.
DuPage Medical Group’s newest CEO has been found in Steve Nelson, the former CEO of UnitedHealthcare.
Jay Duker, chair of ophthalmology at Tufts Medical Center and the Tufts University School of Medicine, has been appointed chief strategic scientific officer of EyePoint Pharmaceuticals.
Dave Marver has been named CEO of GTX Medical. Prior to this role, Marver was CEO of VICIS.
ImCheck Therapeutics has appointed Claude Knopf to the role of chief business officer. Knopf most recently served as chief business officer at Gemini Therapeutics.
Kiadis Pharma has named Ray Barlow as chief business officer and Govert Schouten as head of innovation. Barlow previously served as chief executive officer at e-therapeutics, and Schouten was most recently the founder of Idmon Consulting B.V.
Biotech company Mateon Therapeutics has appointed Giancarlo Mennella to lead its licensing activity for a potential treatment for COVID-19. Mennella is managing director at EGAMID.
Kenneth Huttner has been appointed to the role of senior vice president of clinical development at Neurogene. Prior to this new appointment, Huttner was senior vice president and head of clinical development at LogicBio.
Joseph Wagner has been hired as chief scientific officer of Notable. He was previously the executive director of the University of California Drug Discovery Consortium.
Precision medicine company Oncologie named Matthew Osborne, former chief financial officer at Unum Therapeutics, as the company’s new chief financial officer. Hagop Youssoufian was also appointed by Oncologie to interim chief medical officer. Youssoufian was previously head of experimental medicine at Bristol-Myers Squibb. Oncologie has also hired Bill McDonald as vice president of chemistry, manufacturing and controls (CMC) and Kerry Culm-Merdek as vice president of clinical development. McDonald and Culm-Merdek previously held the respective roles of vice president of CMC at Contrafect and head of clinical pharmacology and quantitative bioanalytics at ImmunoGen.
Scholar Rock has named Tony Kingsley as president and CEO. Kingsley was formerly the president and CEO of Taris Bio.
Allen Nissenson, former emeritus chief medical officer of DaVita Kidney Care, has been named chief medical officer of Sentien Biotechnologies.
Marc Buntaine has been appointed CEO of Synaptive Medical. Buntaine was formerly the executive vice president of sales and marketing for Mobius Imaging.
Andrew Partridge has been named executive vice president and chief commercial officer at Turning Point Therapeutics. Partridge most recently served as chief operating officer and chief commercial officer at Centrexion Therapeutics.
Christopher Slapak has been appointed to the role of chief medical officer of Vor Biopharma. Slapak was formerly the lead of global clinical development for all early-stage oncology compounds at Eli Lilly.
Vijay Modur will be Zikani Therapeutics’ new chief scientific and medical officer. Modur comes to Zikani from Sanofi-Genzyme, where he was global project head in rare disease clinical development.